

Meningioma and Cyproterone Acetate (Synthetic Progestin): Hormone Induced Mutational Shift

Evidence links cyproterone acetate (CPA) to meningioma risk, and CPA and Depo-Provera are linked to multiple skull base tumors

SANTA BARBARA , CA, UNITED STATES, January 9, 2025 /EINPresswire.com/ -- "More evidence is mounting on the association between the use of CPA (cyproterone acetate) and the development of meningiomas. The European Medicines Agency has recently issued restrictions regarding the use of CPA in doses exceeding 10 mg/day because of meningioma risk," states Dr. Mirella Hage, endocrinologist.

Table 2. Characteristics of cyproterone acetate (CPA)-associated meningiomas

Younger age at diagnosis
More common with longer CPA use and higher cumulative dose
Localization in anterior and medial skull base
Multiple
Strong progesterone receptor expression
<i>PIK3CA</i> mutations in 16.7%-34.2%
Stabilization or regression after treatment cessation

Characteristics of cyproterone acetate (CPA)-associated meningiomas

Greg Vigna, MD, JD, national pharmaceutical injury attorney, states, "The DNA footprint of meningiomas in women exposed to Depo-Provera is different when compared with those who develop meningiomas without exposure, which is similar to what is observed with cyproterone acetate. Depo-Provera and CPA both cause meningiomas with an increased tendency for there to be multiple and located at the skull base."



Depo-Provera and CPA both cause meningiomas with an increased tendency for there to be multiple and located at the skull base."

Greg Vigna, MD, JD

What did Dr. Hage report in "Estrogen and Progesterone Therapy and Meningiomas" published in *Endocrinology*,

2022, 163, 1-10? See Table 2.

Read Dr. Hage's article: <https://academic.oup.com/endo/article/163/2/bqab259/6479628>

Dr. Vigna adds, "Depo-Provera and CPA associated meningiomas are both associated with P1k3CA mutations, which is a reshuffling of the frequencies of the known mutations of genes

that cause meningiomas. Depo-Provera, like CPA, causes tumorigenesis and the meningiomas tend to be multiple and located at the skull base.”

Read “Progestin-associated shift of meningioma mutational landscape” published in *Annals of Oncology*. Vol. 29, Issue 3, March 2018, Pg. 681-686: <https://www.sciencedirect.com/science/article/pii/S0923753419354882>

Vigna Law Group is a national litigation firm that focuses on neurological injuries caused by medical malpractice, mid-urethral slings, and drugs including Depo-Provera. His California and Washington DC law firms represents women who required craniotomies for meningiomas with the Ben Martin Law Group, a national pharmaceutical injury law firm in Dallas, Texas.

Read Dr. Vigna’s free book, "[Mother’s Guide to Birth Injury](#)"

[Click here](#) for a free book on Vaginal Mesh Pain by Dr. Vigna.

To learn more, visit the [Meningioma Resection Help Desk](#).

Greg Vigna, MD, JD

Vigna Law Group

+1 817-809-9023

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)



Dr. Greg Vigna

This press release can be viewed online at: <https://www.einpresswire.com/article/775306661>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.